A Phase II, Patient- and Investigator-blinded, Randomized, Placebo-controlled Study to Evaluate Efficacy, Safety and Tolerability of BAF312 (Siponimod) in Patients With Stroke Due to Intracerebral Hemorrhage (ICH)
Phase of Trial: Phase II
Latest Information Update: 15 Feb 2019
At a glance
- Drugs Siponimod (Primary) ; Siponimod (Primary)
- Indications Cerebral haemorrhage
- Focus Therapeutic Use
- Sponsors Novartis; Novartis Pharmaceuticals
- 10 Feb 2019 This trial has been completed in Germany, according to European Clinical Trials Database.
- 19 Apr 2018 Planned End Date changed from 17 Feb 2020 to 17 Mar 2020.
- 19 Apr 2018 Planned primary completion date changed from 17 Feb 2020 to 17 Mar 2020.